KR102263764B1 - Cosmetic or pharmaceutical composition for skin whitening or anti-inflammation comprising cephalomannine or a pharmaceutically acceptable salt thereof - Google Patents

Abstract

The present invention provides a composition for skin whitening or anti-inflammatory, in particular, a cosmetic composition, a pharmaceutical composition, and a health food comprising a compound represented by the following Chemical Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient. The cosmetic or pharmaceutical composition of the present invention has few side effects and is safe to the human body and has excellent skin whitening and anti-inflammatory effects.
[Formula 1]

Description

A cosmetic or pharmaceutical composition for skin whitening or anti-inflammatory comprising cephalomannin or a pharmaceutically acceptable salt thereof {Cosmetic or pharmaceutical composition for skin whitening or anti-inflammation comprising cephalomannine or a pharmaceutically acceptable salt thereof}

The present invention relates to a cosmetic composition, a pharmaceutical composition, and a health food having an excellent effect such as skin whitening or anti-inflammatory, in particular, an excellent effect related to the skin. The present invention also relates to a cosmetic composition, a pharmaceutical composition, and a health food that can exhibit the above effects even in a small amount.

It is a common desire to have fair and fair skin. The color or brightness of the skin is genetically determined according to the concentration and distribution of melanin in the skin of a person, but it is also affected by environmental or physiological conditions such as solar ultraviolet rays, fatigue, or stress. Melanin is produced through a non-enzymatic oxidation reaction after sequentially changing into dopa and dopaquinone by an enzyme called tyrosinase acting as a catalyst in tyrosine, a kind of amino acid. As such, the pathway by which melanin is produced is known, but the cause of tyrosinase triggering in the mechanism of inducing melanin synthesis has not been elucidated in detail.

On the other hand, as a commonly known whitening ingredient, substances that inhibit tyrosinase enzyme activity, such as kojic acid or arbutin, hydroquinone, vitamin C (L-Ascorbic acid) or derivatives thereof and various There are plant extracts. By inhibiting the synthesis of melanin pigment, it is possible not only to realize skin whitening by brightening the skin tone, but also to improve skin hyperpigmentation such as spots or freckles caused by ultraviolet rays, hormones, or heredity. However, when applied to the skin, there is a problem in that the amount of use is limited due to safety issues such as irritation and redness, or the actual effect cannot be expected because the effect is insignificant.

Glycation generally refers to a reaction in which a simple sugar such as glucose or fructose forms a covalent bond with a protein or fat that occurs without the involvement of an enzyme. Glycosylation occurs through a series of complex chemical reactions known as Amadori reactions and Maillard reactions, resulting in the formation of advanced glycation endproducts (AGEs).

On the other hand, the glycosylation process of proteins occurs slowly because enzyme action is not involved, and as a result, proteins with long half-lives such as collagen have a greater effect. As a result of analyzing the final glycated products, glycated collagen was accumulated as the age increased, and the accumulation of final glycated products changed the protein to a harder and more brittle state, and glycated collagen was released from the extracellular matrix of the dermal layer. By preventing collagen from forming an appropriate structure, the skin loses its elasticity and promotes wrinkle formation (Dyer, DG et al, The Journal of Clinical Investigation., 9, p. 2463, 1993).

In addition, the final saccharification product produced by saccharification is a brownish substance and is known to accumulate on the upper dermis layer as skin aging progresses. It is thought to be the causative agent of the gradually turning yellow color of the face as skin aging progresses, and it is known that the more specific final glycation products accumulate, the less reflected light reflected from the skin. While the amount of melanin in the skin has a weak relationship with skin aging, the final glycation products accumulated in the dermal layer of the skin gradually increase as the skin ages and can make the face dull (Hiroshi, O. et al, Skin). Research and Technology, 15, p. 496, 2009)

Aminoguanidine, Pyridoxamine, Aspirin, etc. are known as substances that inhibit glycation. However, these substances have a limited amount of use due to safety concerns on the skin or are practically effective due to insignificant effects. There is a problem that cannot be expected.

Inflammation is the body's immune response to a wound or disease, and oxidative stress such as ultraviolet rays, free radicals, and free radicals activate inflammatory factors, causing various diseases and aging of the skin. Vasoactive polypeptides such as Kinin, Plasmin, or Complement act as vasodilators, contractiles, and chemotaxis, and in addition, lymphocytic such as interleukin-6 (IL-6) Phosphorus and arachidonic acid are responsible for the inflammatory response. Arachidonic acid is metabolized to prostaglandins or leukotrienes, which are inflammatory mediators, through two pathways, Cyclooxygenase or Lipooxygenase, and mediates various inflammatory responses.

On the other hand, in order to eliminate inflammation, an anti-inflammatory agent that acts to remove an inflammatory source, reduce biological reactions and symptoms. Substances used for anti-inflammatory purposes so far include non-steroidal flufenamic acid, ibuprofen, benzydamine or indomethacin, and steroidal prednisolone. Or dexamethasone (Dexamethasone) and the like. In addition, allantoin, azene, or hydrocortisone are known to be effective in anti-inflammatory, but these substances have limitations in usage due to safety issues for the skin, or have insignificant effects, so that no inflammatory relief effect can be expected. have.

Therefore, there is an urgent need for the development of ingredients that are safe in the living body, have stable active ingredients, and above all, have excellent skin whitening and anti-inflammatory effects than conventional substances with skin whitening and anti-inflammatory effects.

Accordingly, the present invention is to solve the above problems, and to provide a novel active ingredient that has few side effects and is safe for the human body and has excellent skin whitening or anti-inflammatory effect, that is, such a useful use of the active ingredient.

In other words, the problem to be solved by the present invention is to provide a composition comprising an active ingredient having excellent efficacy as an active ingredient.

In order to solve the above problems, the present invention provides a composition for skin whitening or anti-inflammatory (improving skin troubles) comprising cephalomannine or a pharmaceutically acceptable salt thereof as an active ingredient, preferably a cosmetic A composition, pharmaceutical composition or health food is provided.

That is, the present invention provides a new use of cephalomannin or a pharmaceutically acceptable salt thereof for skin whitening or anti-inflammatory use.

The inventors of the present invention confirmed that cephalomannin exhibits an anti-glycosylation effect, has an anti-inflammatory effect by suppressing NO production, and exhibits a whitening effect by inhibiting melanin synthesis, and completed the present invention.

In the present invention, the 'whitening effect' refers to not only brightening the skin tone by inhibiting the synthesis of melanin pigment, but also improving skin hyperpigmentation such as spots or freckles caused by ultraviolet rays, hormones, or heredity.

In the present invention, the term 'anti-inflammatory or inflammatory improvement' refers to suppressing inflammation, and the inflammation is one of the defense responses of a living tissue to a certain stimulus, and three types of tissue change, circulatory disorder and exudation, and tissue proliferation. concomitant complex lesions. More specifically, inflammation is part of innate immunity, and as in other animals, human innate immunity recognizes patterns on the surface of cells that are specific to pathogens. Phagocytes recognize cells with such a surface as non-self and attack pathogens. If pathogens break through the body's physical barriers, an inflammatory response occurs. The inflammatory response is a non-specific defense action that creates a hostile environment for microorganisms that invade the wound site. In the inflammatory response, when there is a wound or an external infectious agent enters the body, the white blood cells responsible for the early stage immune response flock and express cytokines. Therefore, the expression level of intracellular cytokines is an indicator of inflammatory response activation. Examples of skin diseases related to inflammation include atopic dermatitis, psoriasis, erythematous diseases triggered by radiation, chemicals, burns, etc., acid burns, bullous dermatosis, lichenoid type disease, itching caused by allergies, seborrheic eczema, acne on roses, pemphigus vulgaris, erythema multiforme, erythema nodosum, balanitis, vulvitis, inflammatory hair loss such as alopecia areata, cutaneous T-cell lymphoma, and the like. In particular, through the anti-inflammatory effect of the present invention, for example, it may have an effect of improving skin troubles such as acne.

The present invention provides a composition comprising a compound represented by the following Chemical Formula 1 or a pharmaceutically acceptable salt thereof in order to solve the above problems and achieve the object of the present invention.

[Formula 1]

The compound represented by Chemical Formula 1 has a molecular formula C ₄₅ H ₅₃ NO ₁₄ , a molecular weight of 831, and is named as Cephalomannine, Taxol B, and the like.

The present invention is not particularly limited to the method for obtaining the cephalomannin, and may be chemically synthesized by a method known in the art, or a commercially available material may be used.

In the cosmetic composition, pharmaceutical composition, and health food according to the present invention, the content of the cephalomannin is preferably 0.00001 to 10% by weight based on the total weight of the cosmetic composition, the pharmaceutical composition and the health food.

"Pharmaceutically acceptable salt" of the present invention refers to salts prepared using organic or inorganic acids or bases with little or no toxicity.

The organic acid is, for example, formic acid, acetic acid, propionic acid, lactic acid, butyric acid, isobutyric acid, trifluoroacetic acid, malic acid, maleic acid, malonic acid, fumaric acid, succinic acid, succinic acid monoamide, glutamic acid, tartaric acid, oxalic acid, citric acid , glycolic acid, glucuronic acid, ascorbic acid, benzoic acid, phthalic acid, salicylic acid, anthranilic acid, dichloroacetic acid, aminooxyacetic acid, benzenesulfonic acid, p-toluenesulfonic acid and methanesulfonic acid salts, and inorganic acids include, for example, hydrochloric acid. , hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, carbonic acid and boric acid salts. Preferably, it may be in the form of hydrochloride or acetate, and more preferably in the form of hydrochloride.

The above-mentioned acid addition salt can be prepared by a) directly mixing the compound of formula 1 and an acid, b) dissolving one of them in a solvent or a hydrous solvent and mixing, or c) dissolving the compound of formula 1 in a solvent or water. It is prepared by a general method of preparing salts by placing them in acid in a solvent and mixing them.

In addition to the above, additional salts available include gaba salt, gabapentin salt, pregabalin salt, nicotinate salt, adipate salt, hemimalonate, cysteine salt, acetylcysteine salt, methionine salt, arginine salt, lysine salt, ornithine salt, Aspartate, etc.

Pharmaceutically acceptable base addition salts include, but are not limited to, salts of sodium, potassium, calcium, ammonium, magnesium or organic amino.

The cephalomannin of the present invention may exist in unsolvated as well as solvated forms including hydrates, ethanolates, and the like. The cephalomannin of the present invention may exist in crystalline or amorphous form, and all such physical forms are included within the scope of the present invention.

The cosmetic composition for skin whitening and anti-inflammatory according to the present invention is a solution, external ointment, cream, foam, nourishing lotion, softening lotion, pack, soft water, emulsion, makeup base, essence, soap, liquid detergent, bath agent, sunscreen cream , sun oil, suspension, emulsion, paste, gel, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation, patch and spray. However, it is not limited thereto.

In addition, the cosmetic composition of the present invention may further include one or more cosmetically acceptable carriers to be formulated in general skin cosmetics, and conventional ingredients include, for example, oil, water, surfactant, humectant, lower alcohol, A thickener, a chelating agent, a colorant, a preservative, a fragrance, etc. may be appropriately mixed, but is not limited thereto.

The cosmetically acceptable carrier included in the cosmetic composition of the present invention varies depending on the formulation. When the formulation of the present invention is an ointment, paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide or Mixtures thereof may be used.

When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder, or a mixture thereof may be used as a carrier component. In particular, in the case of a spray, additional chlorophyll propellants such as fluorohydrocarbons, propane/butane or dimethyl ether.

When the formulation of the present invention is a solution or emulsion, a solvent, solubilizer, or emulsifier is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl benzoate, propylene glycol, 1,3 -butylglycol oil, in particular cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol fatty esters, fatty acid esters of polyethylene glycol or sorbitan.

When the formulation of the present invention is a suspension, as a carrier component a liquid diluent such as water, ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol esters and polyoxyethylene sorbitan esters; Crystalline cellulose, aluminum metahydroxide, bentonite, agar or tracanth may be used.

When the formulation of the present invention is a soap, alkali metal salts of fatty acids, fatty acid hemiester salts, fatty acid protein hydrolysates, isethionate, lanolin derivatives, aliphatic alcohols, vegetable oils, glycerol, sugars, etc. may be used as carrier components. can

The present invention also provides a skin whitening and anti-inflammatory method comprising the step of applying the compound represented by Formula 1 to the skin of an individual. The subject includes, without limitation, mammals including rats, livestock, humans, and the like.

According to another embodiment of the present invention, the present invention provides a pharmaceutical composition for skin whitening or anti-inflammatory containing the compound of Formula 1 as an active ingredient.

The composition comprising the compound of the present invention may be in various oral or parenteral formulations, but preferably parenteral formulations. In the case of formulation, it is prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, and surfactants that are usually used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and such solid preparations include at least one excipient in one or more compounds, for example, starch, calcium carbonate, sucrose or lactose ( lactose), gelatin, etc. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral administration include suspensions, internal solutions, emulsions, syrups, etc. In addition to commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. have. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, and emulsions. Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate.

The present invention may also provide a formulation of an external preparation for skin for skin whitening and anti-inflammatory effects comprising the compound of Formula 1 as an active ingredient.

When the compound of Formula 1 is used as an external preparation for skin, in addition, a fatty substance, an organic solvent, a solubilizer, a thickening agent and a gelling agent, an emollient, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, a surfactant , water, ionic or non-ionic emulsifiers, fillers, sequestering and chelating agents, preservatives, vitamins, blocking agents, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles or common for external applications for the skin It may contain adjuvants commonly used in the field of dermatology, such as any other ingredients used as a dermatome. In addition, the ingredients may be introduced in an amount generally used in the field of dermatology.

When the compound of Formula 1 is provided as an external preparation for skin, it is not limited thereto, but may have a formulation such as an ointment, a patch, a gel, a cream, or a spray.

The pharmaceutical composition of the present invention can be particularly preferably used as a parenteral preparation, for example, the external preparation for skin includes a suitable pharmaceutically acceptable base such as vaseline, stearyl alcohol; suitable pharmaceutically acceptable surfactants such as polysorbate and sorbitan sesquioleate; pharmaceutically acceptable suitable moisturizers such as glycerin; a suitable pharmaceutically acceptable solvent; And it can be prepared by a conventional method for preparing an external preparation for skin in which a flavoring agent, a colorant, a stabilizer, a viscous agent, and the like are homogeneously mixed.

In addition, when the compound of Formula 1 of the present invention is used as a pharmaceutical, it may further contain one or more active ingredients exhibiting the same or similar function. For example, it may contain known skin lightening and anti-inflammatory ingredients. If an additional skin whitening and anti-inflammatory component is included, the skin whitening and anti-inflammatory effect of the composition of the present invention may be further enhanced. When adding the above ingredients, skin safety according to complex use, ease of formulation, and stability of active ingredients can be considered. In one embodiment of the present invention, the composition comprises an anti-inflammatory component known in the art, including a COX-2 inhibitor, prednisolone and allantoin; As a whitening ingredient known in the art, kojic acid (Kojic acid), a substance inhibiting tyrosinase enzyme activity such as arbutin (Arbutin), hydroquinone (Hydroquinone), vitamin-C (L-Ascorbic acid); and one or two or more components selected from the group consisting of derivatives thereof and various plant extracts. Additional ingredients may be included in an amount of 0.0001 wt% to 10 wt% based on the total weight of the composition, and the content range may be adjusted according to requirements such as skin safety and ease of formulation of the compound of Formula 1 .

When the pharmaceutical composition of the present invention contains an effective amount of the compound of Formula 1, it can provide desirable skin whitening effect and anti-inflammatory effect. In the present invention, the term “effective amount” refers to an amount of a compound capable of exhibiting a skin whitening effect or an anti-inflammatory effect.

The effective amount of the compound of Formula 1 included in the composition of the present invention will vary depending on the form in which the composition is commercialized, the method in which the compound is applied to the skin, and the time it stays on the skin. For example, when the composition is commercialized as a pharmaceutical, the compound of Formula 1 may be included at a higher concentration than when commercialized as a cosmetic that is routinely applied to the skin. Accordingly, the daily dose is 0.1 to 100 mg/kg, preferably 30 to 80 mg/kg, and more preferably 50 to 60 mg/kg, based on the amount of the compound of Formula 1, and 1 to It can be administered 6 times.

According to another embodiment of the present invention, there is provided a health food for skin whitening effect and anti-inflammatory effect comprising the compound of Formula 1 above.

As used herein, the term 'health food' refers to food prepared by adding the compound of Formula 1 to food materials such as beverages, teas, spices, gum, and confectionery, or encapsulating, powdering, suspension, etc. It means to bring a specific effect, but unlike general drugs, it has the advantage that there are no side effects that may occur when taking the drug for a long period of time by using food as a raw material. Since the health food of the present invention obtained in this way can be consumed on a daily basis, a high skin whitening effect and an anti-inflammatory effect can be expected, and it is very useful.

When the compound of Formula 1 is used as a food additive, the compound of Formula 1 may be added as it is or used together with other foods or food ingredients, and may be appropriately used according to a conventional method. The mixed amount of the active ingredient may be suitably determined according to the purpose of its use (prevention, health or therapeutic treatment). In general, in the production of food or beverage, the composition of the present invention is added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less, based on the raw material. However, in the case of long-term intake for health and hygiene or health control, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount above the above range. . There is no particular limitation on the type of the food. Examples of foods to which the above substances can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, various soups, beverages, tea, drinks, There are alcoholic beverages, vitamin complexes, and the like, and includes all health foods in the ordinary sense. The health beverage composition of the present invention may contain various flavoring agents or natural carbohydrates as an additional component like a conventional beverage. The above-mentioned natural carbohydrates are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol. As the sweetener, natural sweeteners such as taumatine and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like can be used. The proportion of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 mL of the composition of the present invention. In addition to the above, the health food of the present invention includes various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol , and a carbonation agent used in carbonated beverages. In addition, the health food of the present invention may contain flesh for the production of natural fruit juice, fruit juice beverage, and vegetable beverage. These components may be used independently or in combination. The proportion of these additives is not very important, but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.

Although not limited thereto, in one embodiment of the present invention, the composition may include the compound of Formula 1 in an amount of 0.00001 wt% to 10 wt% based on the total weight of the composition.

The composition containing the cephalomannin or a pharmaceutically acceptable salt thereof of the present invention exhibits a skin whitening effect.

The composition containing the cephalomannin or a pharmaceutically acceptable salt thereof of the present invention exhibits an anti-inflammatory effect or an effect of improving skin troubles.

The composition containing the cephalomannin or a pharmaceutically acceptable salt thereof of the present invention can be used as a safe and excellent cosmetic raw material and pharmaceutical ingredient.

Hereinafter, the following examples and the like will be described in order to explain the present invention in more detail. However, the embodiments according to the present invention may be modified in various other forms, and the scope of the present invention should not be construed as being limited to the embodiments described below. The embodiments of the present invention are provided by way of example to help the specific understanding of the present invention.

Reference example One: cephalomannin ( Cephalomannine ) substance information

[Formula 1]

Substance name: Cephalomannine

CAS No. : 71610-00-9

Molecular Formula: C ₄₅ H ₅₃ NO ₁₄

Molecular Weight: 831

Where to buy: Forever Biotech (China)

Example 1: Anti-inflammatory effect - NO production inhibitory effect

In order to confirm the anti-inflammatory effect and skin trouble alleviation effect of the compound of Formula 1, a nitric oxide (NO) formation inhibitory test was performed by the GRIESS method using the RAW264.7 cell line (ATCC number: CRL-2278).

Specifically, RAW264.7 cells, which are macrophages of mice, were subcultured several times, ^{and placed in a 24-well plate so that 3×10 5} cells were put into each well, and then cultured for 24 hours. Then, the cell medium diluted with the compound of Formula 1 was replaced with a final concentration of 1, 10, and 100 ppm. At this time, L-NMMA (L-NG-Monomethylarginine), a NO-production inhibitor, was treated together as a positive control and incubated for 30 minutes, and 1 μg of LPS (Lipopolysaccharide) was treated as a stimulus and cultured for 24 hours. . Take 100 μl of the supernatant, transfer it to a 96-well plate, add 100 μl of GRIESS solution, react at room temperature for 10 minutes, and measure the absorbance at 540 nm to determine the NO inhibitory effect of the compound of Formula 1, and the result It is shown in Table 1 below.

NO production inhibitory effect of the substance of Formula 1

sample NO production inhibition rate (%) Control (DMSO, 10 ppm) - L-NMMA (positive control, 10 ppm) 41.02 Compound of Formula 1 (1ppm) 14.62 Compound of Formula 1 (10ppm) 18.83 Compound of Formula 1 (100ppm) 56.05

As can be seen from the results of Table 1, it was confirmed that the compound of Formula 1 exhibits excellent activity as a natural material although its activity is low when compared to L-NMMA, a representative anti-inflammatory drug.

Not only can it be used alone in pharmaceutical or cosmetic compositions for improving anti-inflammatory or skin troubles, but also in whitening, wrinkle improvement or skin trouble improvement, anti-inflammatory effect acts as an auxiliary role, so a synergistic effect can be expected

Example 2: Whitening effect-Reducing the total amount of melanin

The whitening effect was confirmed by adding the compound of Formula 1 to the culture medium of B-16 mouse melanoma cells and measuring the total amount of melanin at the cellular level (Lotan R., Lotan D. Cancer). Res . 40:3345-3350, 1980). Before the experiment, toxicity was evaluated for melanoma cells in mice, and a non-toxic concentration was selected for whitening evaluation.

The compound of Formula 1 was added to the culture medium to have final concentrations of 1 ppm and 10 ppm, and arbutin as a control was added to the medium to 100 ppm, treated with B-16 melanoma cells, respectively, and cultured for 3 days.

Thereafter, the cells were treated with trypsin, removed from the culture vessel, centrifuged, and then melanin was extracted. To the detached cells, 1 ml of sodium hydroxide solution (1N concentration) was added and boiled for 10 minutes to dissolve melanin. Using a spectrophotometer, absorbance was measured at 400 nm to measure the amount of melanin produced.

The amount of melanin was measured by a method indicated by the absorbance per unit cell number (1×10 ⁶ cells), the total amount of melanin relative to the control was calculated as the inhibition rate (%), and the results are summarized in Table 4.

Effect of reducing the total amount of melanin at the cellular level according to the concentration

sample melanin production
(abs) Inhibition rate (%) Control (DMSO, 10 ppm) 0.33 - Positive control (arbutin, 100ppm) 0.228 31.06 Compound of Formula 1 (10ppm) 0.273 17.34 Compound of Formula 1 (1ppm) 0.301 8.65

As can be seen from the results of Table 2, it was found that the compound of Formula 1 exhibited an excellent effect of reducing the total amount of melanin at a low concentration and thus can be used for whitening purposes.

Example 3: anti-glycosylation effect

In order to confirm the anti-glycation efficacy, the glycation inhibitory activity was measured using L-arginine and glucose.

First, prepare by dissolving 1M L-arginine and 1M glucose using 1M phosphate buffer (pH 7.4), and dilute the sample to 50 and 100ppm using 1M phosphate buffer. Mix 1M L-arginine and 1M phosphate buffer in a ratio of 1 to 4, then dispense 80 μl of each in a 96-well plate. To this, add 100 μl each of a sample diluted to 50 and 100 ppm and 0.01M aminoguanidin to be used as a positive control. After mixing these samples well, finally add glucose diluted with 1M phosphate buffer so that the final concentration of glucose is 0.1M. The reaction was carried out at 70°C for 4 hours. The degree of glycosylation was measured by measuring the absorbance at 420 nm of the 96-well plate using a spectrophotometer.

The glycation experimental group of the following formula is an experimental group in which glycation was induced by adding 1M L-arginine and 1M glucose. In order to measure the absorbance of the sample itself, only 1M L-arginine and the sample were added and the absorbance was measured at 420 nm. did. The glycation inhibitory activity can be calculated as follows.

Anti-glycosylation effect of compound of formula 1

sample Inhibition rate (%) Control (DMSO, 50 ppm) - Positive control (Aminoguanidine, 55ppm) 54.89 Compound of Formula 1 (50ppm) 69.98 Compound of Formula 1 (25ppm) 42.11

As can be seen from the results of Table 3, the compound of Formula 1 is considered to have an excellent anti-glycosylation effect and thus have a whitening effect.

Claims (4)

A cosmetic composition for skin whitening comprising a compound represented by the following Chemical Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
[Formula 1]

A health food composition for skin whitening comprising a compound represented by the following Chemical Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
[Formula 1]

The cosmetic composition according to claim 1, wherein the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof is included in an amount of 0.00001 to 10% by weight based on the total weight of the cosmetic composition. The health food composition according to claim 2, wherein the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof is included in an amount of 0.00001 to 10% by weight based on the total weight of the health food composition.